Lifeward Ltd. announced that Aetna has granted a prior authorization for a Medicare Advantage beneficiary to obtain its ReWalk Personal Exoskeleton, extending coverage to the three largest Medicare Advantage insurers—Aetna, UnitedHealthcare and Humana—and reaching roughly 16 million beneficiaries nationwide.
The expansion follows earlier approvals from Humana on December 3 2025 and UnitedHealthcare on November 17 2025, making Lifeward the first company to secure coverage from all three major payers in the U.S. Medicare Advantage market.
By removing a key reimbursement barrier, the new authorizations are expected to accelerate unit placements and revenue generation. The 16 million‑beneficiary footprint represents a significant portion of the Medicare Advantage population, positioning Lifeward to capture a larger share of the growing exoskeleton market.
Mark Grant, CEO of Lifeward, said, "Aetna's decision represents meaningful progress in expanding access to evidence‑based advanced rehabilitation technology. As leading Medicare Advantage insurers independently review the clinical evidence and reach consistent medical necessity determinations, it reinforces that exoskeleton‑assisted walking serves as an appropriate therapeutic intervention for qualified individuals living with spinal cord injury."
The coverage milestone comes amid Lifeward’s broader strategy to secure payer approvals and expand commercial traction in the U.S. market. The company also announced a strategic partnership with Oramed Pharmaceuticals on January 13 2026, which could provide up to $47 million in funding and integration of Oramed’s oral delivery platform, further diversifying Lifeward’s revenue streams.
Lifeward’s progress is built on the Medicare brace benefit category that was finalized in November 2023 and became effective on January 1 2024, creating a formal reimbursement pathway for personal exoskeletons. The new authorizations reinforce the viability of that pathway and signal growing acceptance of exoskeleton technology among major payers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.